An ever-increasing demand for biomolecule-based therapies is driving biopharmaceutical companies to accelerate process development activities to remain competitive in today’s industry. Within the downstream process development space, affinity chromatography is widely used for primary capture of monoclonal antibodies, Fc fusion proteins, etc. Optimization of this step requires determination of dynamic binding capacity (DBC) for target protein molecule and can be a lengthy process using traditional methods. KBI Biopharma has applied the use of variable pathlength technology for rapid generation of breakthrough curves and determination of DBC for capture resin selection. FlowVPE, a variable pathlength UV detector from Repligen, is integrated with the chromatographic system for real time generation of breakthrough curves, reducing the time and cost associated with the development of the primary capture step. This technology helps accelerate the overall process development timeline.

Speaker: Rashmi Bhangale, Ph.D., Downstream Process Development Scientist – KBI Biopharma.